Total Valuation
BioMark Diagnostics has a market cap or net worth of €36.87M. The enterprise value is €48.82.
Market Cap€36.87M
Enterprise Value€48.82
Share Statistics
BioMark Diagnostics has 106,483,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding106,483,440
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioMark Diagnostics’s return on equity (ROE) is -4.46 and return on invested capital (ROIC) is -163.31%.
Return on Equity (ROE)-4.46
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-163.31%
Return on Capital Employed (ROCE)-2.45
Revenue Per Employee6.64K
Profits Per Employee-164.13K
Employee Count9
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioMark Diagnostics is ―. BioMark Diagnostics’s PEG ratio is 1.07.
PE Ratio―
PS Ratio1001.91
PB Ratio180.94
Price to Fair Value180.94
Price to FCF-54.80
Price to Operating Cash Flow-54.05
PEG Ratio1.07
Income Statement
In the last 12 months, BioMark Diagnostics had revenue of 59.79K and earned -1.48M in profits. Earnings per share was -0.01.
Revenue59.79K
Gross Profit-322.49K
Operating Income-1.87M
Pretax Income-1.60M
Net Income-1.48M
EBITDA-1.49M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -1.09M and capital expenditures -4.23K, giving a free cash flow of -1.09M billion.
Operating Cash Flow-1.09M
Free Cash Flow-1.09M
Free Cash Flow per Share-0.01
Dividends & Yields
BioMark Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change38.46%
50-Day Moving Average0.32
200-Day Moving Average0.30
Relative Strength Index (RSI)52.00
Average Volume (3m)0.00
Important Dates
BioMark Diagnostics upcoming earnings date is Aug 31, 2026, TBA (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateAug 31, 2026
Ex-Dividend Date―
Financial Position
BioMark Diagnostics as a current ratio of 0.99, with Debt / Equity ratio of 218.95%
Current Ratio0.99
Quick Ratio0.99
Debt to Market Cap<0.01
Net Debt to EBITDA-0.07
Interest Coverage Ratio-29.59
Taxes
In the past 12 months, BioMark Diagnostics has paid -126.23K in taxes.
Income Tax-126.23K
Effective Tax Rate0.08
Enterprise Valuation
BioMark Diagnostics EV to EBITDA ratio is -40.29, with an EV/FCF ratio of -54.90.
EV to Sales1.00K
EV to EBITDA-40.29
EV to Free Cash Flow-54.90
EV to Operating Cash Flow-55.11
Balance Sheet
BioMark Diagnostics has €1.01M in cash and marketable securities with €724.86K in debt, giving a net cash position of €286.05K billion.
Cash & Marketable Securities€1.01M
Total Debt€724.86K
Net Cash€286.05K
Net Cash Per Share<€0.01
Tangible Book Value Per Share<€0.01
Margins
Gross margin is -371.39%, with operating margin of -3130.74%, and net profit margin of -2470.76%.
Gross Margin-371.39%
Operating Margin-3130.74%
Pretax Margin-2681.89%
Net Profit Margin-2470.76%
EBITDA Margin-2491.34%
EBIT Margin-3130.74%
Analyst Forecast
The average price target for BioMark Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-63.46%
EPS Growth Forecast36.23%